Pfizer, Inc. · NYSE:PFE

Pfizer — 41st Annual J.P. Morgan Healthcare Conference 2023

7 slides from Pfizer's conference presentation, Jan 9, 2023

  1. Slide 1: Fireside Chat - 41st Annual J.P. Morgan Healthcare Conference

    Fireside Chat - 41st Annual J.P. Morgan Healthcare Conference Dr. Albert Bourla, DVM, PhD, Chairman & CEO Monday, January 9, 2023 1

  2. Slide 2: Forward-Looking Statements and Other Notices

    Forward-Looking Statements and Other Notices This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We may include forward-looking statement

  3. Slide 3: Pfizer Non-COVID Potential Revenue Projections Based on Internal Expectations

    Pfizer Non-COVID Potential Revenue Projections Based on Internal Expectations For illustrative purposes only and not intended to be at scale. All values at constant exchange rates. Preliminary, subject to change, and subject to, among other risks, assumptions and uncertainties, clinical trial, regul

  4. Slide 4: Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030

    LOEs Key Products Included in the Expected ~$17 Billion in LOE Revenue Declines from 2025-2030 2021 WW 2021 U.S. 2021 Dev. EU Year of Year of Revenues Revenues Revenues Expected U.S. Expected EU Product ($ millions) ($ millions) ($ millions) LOE LOE Eliquis $5,970 $3,160 $1,520 2026* 2026 Inlyta $1,

  5. Slide 5: New Launches / Co-promotions and Potential Product Launches

    Introduction New Launches / Co-promotions and Potential Product Launches1 Product Candidate Anticipated Indication Expected Launch New Molecular Entity (NME) Launches Ngenla (Ex-US) Growth Hormone Deficiency 2022 Ritlecitinib Alopecia Areata 2023 Elranatamab Triple Class Relapsed or Refractory (Resi

  6. Slide 6: Additional Pipeline Potential Launches Through 2030 – Selected Examples

    Introduction Additional Pipeline Potential Launches Through 2030 – Selected Examples Product Candidate Anticipated Indication(s) Expected Potential Launch New Molecular Entity (NME) Launches Danuglipron or PF’1532 (oral GLP1s) Type 2 Diabetes, Obesity >2024 Anti-IFN-β Antibody (PF’3859) Dermatomyosi

  7. Slide 7: Fortifying our Long-Term Growth Plans – as presented on Dec. 12

    Closing Fortifying our Long-Term Growth Plans – as presented on Dec. 12 Illustrative* 2025-2030 Projections ~$20B4 Key drivers At least • INF-Beta $25B3 • GLP1 ~$17B2 Key drivers • TTI-622 • RSV • mRNA • Elranatamab • Ritlecitinib Key drivers • Talzenna+ Xtandi • Migraine Franchise • Oxbryta + GBT-6

Pfizer — 41st Annual J.P. Morgan Healthcare Conference 2023 on 6ix